Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour Application

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Christopher Ta, Stanford University
ClinicalTrials.gov Identifier:
NCT00466570
First received: April 25, 2007
Last updated: June 12, 2013
Last verified: June 2013
  Purpose

Topical ophthalmic antibiotics are common prescribed just prior to eye surgery to lower the risk of infection. Previous studies have suggested that antibiotics containing a preservative (Zymar) kill bacteria much quicker than those without a preservative (Vigamox). The purpose of this research is to compare how quickly to the two commonly prescribed antibiotics eliminate bacteria from the eye surface.


Condition Intervention
Conjunctical Flora
Drug: gatifloxacin, moxifloxacin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Single Blind
Primary Purpose: Prevention
Official Title: Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Antibiotic killing of conjunctival bacterial flora 1 hour after application

Enrollment: 0
Study Start Date: April 2007
  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age- older than 50 years of age
  • Diagnosis- Cataract or had cataract surgery

Exclusion Criteria:

  • Systemic or topical antibiotic treatment within 30 days
  • Use of systemic or topical steroids
  • Active ocular infection
  • Ocular surgery in the past 6 months
  • Allergy to fluoroquinolones
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00466570

Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Christopher Ta, MD Stanford University
  More Information

Publications:
Responsible Party: Christopher Ta, Principal Investigator, Stanford University
ClinicalTrials.gov Identifier: NCT00466570     History of Changes
Other Study ID Numbers: 8924
Study First Received: April 25, 2007
Last Updated: June 12, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Gatifloxacin
Moxifloxacin
Fluoroquinolones
Norgestimate, ethinyl estradiol drug combination
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Bacterial Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 23, 2014